← Back to Clinical Trials
Recruiting NCT07585214

NCT07585214 Prospective Multicenter Screening for Thoracic Disease Via Radiography

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07585214
Status Recruiting
Phase
Sponsor Chinese Academy of Sciences
Condition Pulmonary Diseases
Study Type OBSERVATIONAL
Enrollment 300,000 participants
Start Date 2026-05-01
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300,000 participants in total. It began in 2026-05-01 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This multicenter, prospective study aims to evaluate the real-world clinical utility of chest X-ray (CXR) for large-scale thoracic disease screening. Adult participants presenting for health examinations will undergo digital CXR screening, and any suspected abnormalities will be confirmed via a gold standard reference, such as a chest CT scan or clinical follow-up. The primary outcome measure is the detection rate (screening yield) of confirmed thoracic conditions. Secondary measures will assess diagnostic accuracy (sensitivity and specificity), false-positive rates, and multi-center reading consistency. By providing prospective, large-cohort evidence, this research seeks to validate the cost-effectiveness and feasibility of CXR in identifying early-stage lung, pleural, and cardiac abnormalities, ultimately guiding public health strategies and optimizing early medical intervention.

Eligibility Criteria

Inclusion Criteria: * Age over 18. * Ability to understand and willingness to sign a written informed consent form. * Individuals presenting for routine health examinations or community-based screening. Exclusion Criteria: * Women who are pregnant, lactating, or planning to become pregnant during the study period. * Physical limitations preventing stable positioning or breath-holding, or presence of metallic implants that may significantly degrade image quality. * Known history of advanced thoracic diseases currently under treatment (e.g., active lung cancer, end-stage pulmonary fibrosis, or congestive heart failure). * Individuals who have undergone chest CT or X-ray examinations within the past 3 months.

Contact & Investigator

Central Contact

Zeyu Zhang, Ph.D.

✉ zhangzeyu@fingerpass.net.cn

📞 +86 15510661612

Frequently Asked Questions

Who can join the NCT07585214 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07585214 currently recruiting?

Yes, NCT07585214 is actively recruiting participants. Contact the research team at zhangzeyu@fingerpass.net.cn for enrollment information.

Where is the NCT07585214 trial being conducted?

This trial is being conducted at Dazhou, China.

Who is sponsoring the NCT07585214 clinical trial?

NCT07585214 is sponsored by Chinese Academy of Sciences. The trial plans to enroll 300,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology